Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — RBC Capital Markets Global Healthcare Conference 2018
18 slides from Evofem Biosciences's conference presentation, Feb 20, 2018
Slide 1: Presentation at RBC Capital Markets Global Healthcare Conference
Presentation at RBC Capital Markets February 21, 2018 Global Healthcare Conference NASDAQ: EVFM Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,” “plan,” “aim,”
Slide 3: Our Mission
Evofem Biosciences is developing innovative products to fill unmet needs of women in reproductive and sexual health Our Mission
Slide 4: About Evofem Biosciences
Nasdaq-listed 18 Jan 2018 “EVFM”, $20M investment from Invesco Asset Mgmt. Next-generation women’s health company Amphora® poised to compete in $5.7B Rx contraceptive market1 On demand, woman-controlled, hormone-free vaginal gel Top-line results from confirmatory Phase 3 trial expected Q1 2019 Addit
Slide 5: Seasoned Management Team with Established Track Record of Clinical and Commercial Execution
Seasoned Management Team with Established Track Record of Clinical and Commercial Execution Officer / Title Selected Achievements Saundra Pelletier Chief Executive Officer & President Extensive global experience as a pharmaceutical executive, entrepreneur and advocate for women’s health Founding CEO
Slide 6: Evofem Pipeline: Targeting High-Value Opportunities
Phase 1 Phase 2b Phase 3 Target population (U.S.) Amphora Contraception 43M women1 Prevention of Chlamydiaa 1.6M new cases in 20162 Prevention of Gonorrhea* 468,000 new cases in 20162 Antimicrobial Multipurpose Prevention Technology Vaginal Gel Recurrent Bacterial Vaginosis* 21M women3 Evofem Pipeli
Slide 7: The Time is Right for a Contraception Revolution
The Time is Right for a Contraception Revolution Amphora Est.
Slide 8: Will Women Use Amphora?
Women manage their fertility for decades Contraception is switched 3-4 times throughout their lifetime due to side effects driven by hormones Loss of libido, headaches, moodiness, nausea Nontraditional forms of contraception have led to U.S. market growth of $700M over the last 5 years1 43M women ar
Slide 9: Amphora: Effective Contraception, Excellent Safety & Tolerability Profile
Acid-buffering properties Maintains acidic vaginal environment, preventing the survival of spermatozoa The introduction of semen into the vagina raises the pH to 6.0 Amphora maintains the natural vaginal pH, inhibiting spermatozoa Highly bioadhesive, forming a layer over vaginal and cervical surface
Slide 10: Phase 3 Comparative Contraceptive Trial: AMP001
Multicenter, randomized, open-label trial Primary endpoint: Contraceptive efficacy compared to Conceptrol (nonoxynol-9) 3,400 women at 62 sites (49 U.S., 13 Russia)1 No safety concerns Phase 3 Comparative Contraceptive Trial: AMP001 Source: Company materials, ClinicalTrials.gov. 18-35 year old adult
Slide 11: Results and Safety Data of AMP001 Phase 3 Clinical Trial
April 28, 2016: Complete Response Letter (CRL) Issues outlined: Russian subjects considered not generalizable to the U.S. population Certain cycles excluded from analysis Cycle 0 Cycles <21 days or >42 days Results and Safety Data of AMP001 Phase 3 Clinical Trial 6 Months Amphora 6 Months Conceptrol
Slide 12: Confirmatory Phase 3 Trial: Amphora for Contraception
Single-arm, open label, trial in 115 U.S. sites Primary endpoint: Contraceptive efficacy over seven cycles 1,350 women, 18-35 years old 5 gram doses of Amphora administered up to one hour before intercourse Exploratory endpoint: sexual satisfaction Top-line results expected Q1 2019 Confirmatory Phas
Slide 13: Amphora for Prevention of STIs
Phase 2b/3 trial underway Double-blinded placebo-controlled efficacy trial 850 women, 18-35 years old, with chlamydia or gonorrhea infection in past 4 months 20 U.S. sites Four-month interventional period + one-month follow-up Primary objective: Prevention of chlamydia trachomatis in women Secondary
Slide 14: Phase 2b/3 Clinical Trial: MPT for Bacterial Vaginosis
BV ~40% recurrence rate1 Phase 1 dose-finding study completed pH levels maintained to seven days Trial design in development Differentiated formulation under assessment Anticipated to enroll ~230 women at up to 36 U.S sites Anticipated First Patient In: Q4 2018 FDA designated as a Qualified Infectio
Slide 15: Key Stock Data
Nasdaq: EVFM Shares outstanding 17.8M 52-week range (02/15/2018) $1.80 - $15.78 Recent share price (02/15/2018)$ 7.06 Market Cap (02/15/2018)$125.4M Key Stock Data
Slide 16: Multiple Near-term Catalysts Anticipated
Multiple Near-term Catalysts Anticipated Initiated Phase 2b/3 Amphora STI trial (first patient in) Jan 2018 Completed enrollment in Phase 3 Amphora contraceptive trial Feb 2018 Initiate Phase 2b/3 MPT vaginal gel BV trial (first patient in) Q4 2018 Top-line results from Phase 3 Amphora contraceptive
Slide 17: Why Evofem? Why Now?
Leveraging MPT vaginal gel technology platform to develop and commercialize novel, first-in-class products for women Preparing lead candidate Amphora for 2020 entry into $5.7B U.S. Rx contraceptive market* Addresses significant gaps in the market -- on demand, woman-controlled, hormone-free contrace
Slide 18: Evofem Biosciences
E¥OFEM BIOSCIENCES"
Evofem Biosciences — RBC Capital Markets Global Healthcare Conference 2018 on 6ix